Curis to Present at the Needham Biotechnology Conference
Wednesday May 18, 8:30 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2005--Curis, Inc. (NASDAQ: CRIS - News), a therapeutic drug development company, today announced that the Company will be presenting at the Fourth Annual Needham Biotechnology Conference on Wednesday, May 25, at the New York Palace Hotel in New York City.
Daniel Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of Curis' business and collaborations at 1:30 p.m. EDT. There will be an audio webcast of the presentation at:
wsw.com
The presentation will be archived shortly after the live event and available for 30 days following the conference. The presentation will also be available on the Investor Relations section of Curis' website at www.curis.com.
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer (under collaboration with Genentech, which also includes a co-development arrangement for a basal cell carcinoma product candidate), kidney disease (licensed to Ortho Biotech Products, a subsidiary of Johnson & Johnson), neurological disorders (under collaboration with Wyeth), hair growth, and cardiovascular disease. For more information, please visit the Curis web site at www.curis.com. |
